Biotech

All Articles

AstraZeneca articles records on in-house opponents to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared an early check out the performance of its internal antibody-drug co...

iTeos- GSK's TIGIT celebrity shows relevant enhancement

.After announcing a stage 3 launch based upon favorable midstage end results, iTeos and also GSK are...

More collaborative FDA can speed up rare ailment R&ampD: report

.The FDA ought to be actually even more open and also collective to let loose a rise in approvals of...

Zenas, MBX, Bicara head to Nasdaq in very hot day for biotech IPOs

.It is actually an extraordinarily active Friday for biotech IPOs, along with Zenas BioPharma, MBX a...

Atea's COVID antiviral neglects to halt hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has neglected another COVID-19 trial, however the biotech still kee...

Neurocrine's bid to save schizophrenia prospect fails

.Neurocrine Biosciences' schizophrenia course pivot has neglected. The biotech was unable to reprodu...

Sanofi spends $110M upfront for late-stage radioligand treatment

.Sanofi has brought in a late entry to the radioligand celebration, paying 100 thousand euros ($ 110...

F 2G increases $100M for second try to acquire brand-new antifungal to market

.After F2G's 1st try to get a brand-new course of antifungal to market was hindered by the FDA, the ...

Moderna targets $1.1 B in R&ampD costs slices, falls 5 plans among productivity tensions

.Moderna has sworn to cut R&ampD investing through $1.1 billion by 2027. The decision to shrink the ...

Sanofi's $80M bank on Key dystrophy medication finishes in period 3 go bust

.Merely 4 months after Sanofi wager $80 million in upfront cash on Key Rehabs' losmapimod, the cours...